Sam Fassnacht
Medical · Patchogue, NYNPI 1558670463
Payments from drug & device makers
Across 252 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$783
- AbbVie$529
- Lilly USA, LLC$486
- GSK$472
- Amgen$446
- Novo Nordisk$398
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,83699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $783 |
| AbbVie | 28 | $529 |
| Lilly USA, LLC | 27 | $486 |
| GSK | 23 | $472 |
| Amgen | 18 | $446 |
| Novo Nordisk | 22 | $398 |
| Boehringer Ingelheim | 19 | $367 |
| Pfizer | 18 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $222 |
| Astellas Pharma US Inc | 7 | $144 |
| Amarin Pharma, Inc. | 8 | $143 |
| Merck | 6 | $96 |
| Redhill Biopharma Inc. | 5 | $87 |
| Johnson & Johnson | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Eisai Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Bausch Health US, LLC | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
How this compares
$4,882 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $52,781 |
| EliquisApixaban | 28 | $39,766 |
| JardianceEmpagliflozin | 29 | $38,065 |
| FarxigaDapagliflozin Propanediol | 18 | $27,966 |
| MounjaroTirzepatide | 18 | $20,018 |
| VascepaIcosapent Ethyl | 11 | $8,805 |
| Rosuvastatin Calcium | 206 | $2,671 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 11 | $2,348 |
| Pitavastatin Calcium | 14 | $2,244 |
| Levothyroxine Sodium | 161 | $2,170 |
| SynthroidLevothyroxine Sodium | 28 | $1,802 |
| Atorvastatin Calcium | 189 | $1,592 |
| PaxlovidNirmatrelvir/Ritonavir | 13 | $1,429 |
| Metoprolol Succinate | 108 | $1,359 |
| Pantoprazole Sodium | 101 | $1,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $398 | $52,78146 claims |
| PfizerEliquis, Paxlovid | $355 | $41,19641 claims |
| Boehringer IngelheimJardiance | $367 | $38,06529 claims |
| AstraZenecaFarxiga | $783 | $27,96618 claims |
| Lilly USA, LLCMounjaro | $486 | $20,01818 claims |
| AbbVieSynthroid | $529 | $1,80228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Patchogue
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.